Quantum companies
Build an investable spinout and a lasting university partnership
A quantum spinout sought a commercial starting point that investors could understand while maintaining the university relationships, facilities and research essential to its development.
01 / The context
The situation.
A quantum sensing team was preparing a company around university research. Its product depended on a patent application, laboratory software, experimental know-how and specialist facilities. The scientific founder expected to retain an academic role.
The venture's starting position therefore combined formal rights with the practical capacity to use them. Continued links with the laboratory were part of the business question, alongside the resources needed to develop a company with its own priorities.
02 / The challenge
The decision that matters.
The proposed licence addressed the patent application, but the business also needed people, equipment and continuing access to research. University colleagues needed publication opportunities; investors needed a credible development plan. The founders had to decide what the company needed to control, what it could share and which dependencies it could sustain.
A licence alone did not resolve access to the people and facilities behind the research. Equally, a continuing academic relationship needed to accommodate commercial development. The difficulty was to give both ambitions a credible place without treating future access or founder availability as automatic.
03 / The strategic perspective
Build the business around usable scientific capability.
University research can provide the foundation of a company while remaining part of a continuing scientific relationship. The strategic issue is how that relationship supports the venture as its commercial responsibilities grow. Formal rights, practical expertise, facilities and the founder's availability each contribute differently to the ability to develop a product.
An investable starting point therefore needs more than a description of the invention. It needs a credible connection between what the company can access, what it needs to build for itself and what both sides expect from continued collaboration. Publication and commercial development belong within that same conversation.
04 / DELSOL Group’s contribution
How DELSOL Group contributed.
An investable commercial position
DELSOL Group connected the proposed rights package with the product and financing ambitions, helping founders and counsel frame priorities for negotiating existing assets, future developments and commercial access. The commercial question was how the proposed package related to the business the founders intended to finance. Discussion of rights remained connected with the capabilities needed to make those rights useful.
A valuable research relationship
DELSOL Group helped leaders frame publication, collaboration and confidentiality choices around their respective interests, supporting discussions about a university relationship with room for scientific recognition and a viable company proposition. Scientific recognition and commercial development had different demands on the same knowledge. DELSOL Group kept those interests connected in the discussion of what the relationship needed to support over time.
Capacity beyond the founding laboratory
Through fractional intangible-asset leadership, DELSOL Group connected founder availability, knowledge transfer and facility dependence with investment decisions, bringing the resources needed for greater company independence into board discussions. This linked independence with resources, rather than treating it simply as a question of ownership. The board conversation included what continued reliance on the laboratory meant for the company's development ambitions.
05 / Intended value
The business objective.
The objective was to support a more coherent venture: to clarify its starting position and development dependencies for investors, and the value of continuing collaboration for the university. The aim was to give founders clearer choices about the capital, capabilities and agreements needed to turn scientific promise into a sustainable business.
The intended value lay in a financing discussion that reflected how the venture would actually operate. Commercial access, scientific relationships and the resources for greater independence needed to form a consistent proposition, rather than separate assumptions about the company's future.